This Funding Opportunity Announcement (FOA) invites applications for support of pre-clinical studies to repurpose existing experimental or FDA approved drugs or biologics (existing therapeutics) that have already begun or completed at least a Phase l trial. The hypothesis for proposed studies must be developed using innovative processes to identify the therapeutic/indication pair. Examples include independent crowdsourcing strategies (e.g., http://www.ncats.nih.gov/ntu/assets/current, http://openinnovation.astrazeneca.com/, or any website that lists experimental therapies), or use of computational algorithms.
The initial UG3 award will support the development of milestone-driven rigorous, pre-clinical target engagement and/or efficacy studies. Once UG3 pre-clinical milestones have been met, the UH3 award may be made to support clinical trial planning: this includes complete planning, design, and preparation of the documentation necessary for implementation of Phase I and/or Phase II clinical trials for a new therapeutic use.
- Letter of Intent Due Date(s): 30 days prior to the application due date
- Application Due Date(s):New Dates October 30, 2017, February 28, 2018, June 26, 2018, October 30, 2018, February 27, 2019, June 26, 2019, October 30, 2019, February 27, 2020, June 26, 2020, and October 30, 2020
PAR-17-465 Expiration Date New Date October 31, 2020 per issuance of NOT-TR-20-025. (Original Expiration Date: September 8, 2020 )